Financial Data and Key Metrics Changes - The company reported strong financial results for Q4 2021 and the full year, with significant growth in testing revenues driven by COVID-19 testing [4][11] - The company highlighted that despite an impairment charge of $3.75 million, the operational performance remained robust, with EBITDA being a key focus to correct for non-cash issues [32][11] Business Line Data and Key Metrics Changes - The diagnostics business saw a substantial increase in testing volume, performing 350,000 tests in Q4 2021 compared to 110,000 in the first quarter of the previous year, indicating a tripling of testing capacity [40] - The company plans to diversify its clinical lab services beyond COVID-19 testing, aiming to build a fully functional and diversified clinical lab [8][11] Market Data and Key Metrics Changes - The company has expanded its customer base significantly, growing from a few major customers to approximately a dozen, which has helped maintain testing volumes even as COVID-19 cases fluctuate [9][10] - The company is well-positioned to handle potential new COVID-19 variants, with ongoing testing services expected to remain robust [10][24] Company Strategy and Development Direction - The company aims to leverage its distribution network to expand direct-to-consumer genomic testing and retail distribution of Nebula's genomic sequencing products [3][12] - The strategic focus includes building partnerships and research collaborations to enhance precision medicine capabilities, with an emphasis on whole genome sequencing [12][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued demand for testing services, even as COVID-19 cases decline, citing the importance of testing in controlling the spread of the virus [10][24] - The company anticipates a strong first quarter of 2022, with expectations of record financial results compared to both the previous quarter and the same quarter last year [40] Other Important Information - The company has a strong cash position and working capital, allowing for potential stock buybacks and dividends in the future [6][19] - The acquisition of Nebula Genomics is seen as a significant growth opportunity, with expectations that it could become more valuable than the company's current market cap [18][19] Q&A Session Summary Question: Current trend of COVID-19 testing volume and potential for the current quarter - Management noted that while Omicron cases have dropped, a new sub-variant BA.2 is emerging, which could lead to increased testing demand [22][24] Question: Price reduction for Nebula Genomics test and retail availability - Management indicated that price reductions and retail distribution are expected in the second half of the year, with ongoing negotiations for strategic partnerships [25][27] Question: Impairment charge and its implications - Management confirmed that the impairment charge was non-cash and related to a loan, with hopes of recovering the amount in the future [32][34] Question: Stock buyback strategy - Management stated that stock buybacks and dividends are possibilities, with decisions made in the best interest of long-term shareholders [35][36] Question: Testing volume comparison for March - Management provided testing volume figures, indicating a strong performance in both February and March, with expectations for continued robust testing levels [40][41]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact name of registrant as specified in its charter) WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission file number 000-21617 ProPhase Labs, Inc. Delaware 23-2577138 (State or other jurisdi ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q3 2021 Earnings Conference Call November 12, 2021 11:00 AM ET Company Participants Jules Abraham – Investor Relations CORE IR Ted Karkus – Chairman and Chief Executive Officer Conference Call Participants Patrick Patterson – Private Investor Fred MacDonald – Private Investor George Gianakos – Private Investor Operator Welcome to the ProPhase Labs Third Quarter 2021 Financial Results and Corporate Update Conference Call. All participants will be in listen-only mode. [Operat ...

ProPhase 1 NASDAQ: PRPH Corporate Presentation September 2021 Forward Looking Statements This presentation contains forward‐looking statements relating to our strategy and business objectives. All statements other than statements of historical facts included in this presentation may be deemed to be forward‐looking statements including statements related to our plans to grow our new whole genome sequencing (WGS) business by leveraging our existing CLIA labs and retail relationships and to build a genomics da ...

1 ProPhase NASDAQ: PRPH Corporate Presentation August 2021 Forward Looking Statements This presentation contains forward‐looking statements relating to our strategy and business objectives. All statements other than statements of historical facts included in this presentation may be deemed to be forward‐looking statements including statements related to our plans to grow our new whole genome sequencing (WGS) business by leveraging our existing CLIA labs and retail relationships and to build a genomics datab ...

Financial Data and Key Metrics Changes - The company reported a disappointing second quarter with significant revenue drops due to regulatory changes affecting COVID testing, despite having built a state-of-the-art lab capable of processing 50,000 tests per day [20][27] - Non-GAAP results indicated that the company did not incur a loss when excluding non-cash charges, which were primarily related to stock options [21][75] - The company paid a special stock dividend of approximately $4.5 million, which was funded by about six weeks of cash flow, indicating strong cash levels despite the reported loss [20][22] Business Line Data and Key Metrics Changes - The dietary supplement business is growing nicely, with widespread distribution and strong demand, which positions the company well for future product introductions [23][24] - The COVID testing business experienced a significant decline in revenue during the second quarter due to a drop in COVID incidents and regulatory changes, impacting expected revenues from events like proms and graduations [20][19] Market Data and Key Metrics Changes - The company has secured large RFPs from the township of Oyster Bay and Dutchess County, which could lead to substantial business opportunities as COVID testing demand resurges [29][28] - The positivity rates for COVID have increased significantly, indicating a potential rebound in testing demand, which the company is well-positioned to capitalize on [28][74] Company Strategy and Development Direction - The company is focusing on diversification through acquisitions, including the recent acquisition of Nebula Genomics, which is expected to be transformational for its business model [8][40] - The strategy includes expanding into traditional laboratory testing beyond COVID, with plans to acquire additional labs [10][36] - The company aims to leverage its existing distribution channels to market new genomic products effectively, similar to its previous success with dietary supplements [66][54] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing a strong customer base returning as COVID testing demand increases again [28][72] - The CEO highlighted the importance of genomic sequencing in future healthcare and the inevitability of insurance companies adopting these services as costs decrease [80][79] - The company is building an advisory board with leading experts in genomics to enhance its strategic direction and market position [42][45] Other Important Information - The company has a strong cash position and net working capital, which remained stable despite the challenges faced in the second quarter [22][72] - Management emphasized the importance of customer service and IT capabilities in maintaining competitive advantages in the testing market [18][72] Q&A Session All Questions and Answers Question: Insights on genomic sequencing and insurance companies - The CEO acknowledged that it is inevitable for insurance companies to adopt genomic sequencing as costs decrease, which will lead to broader acceptance and payment for these services [80]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission file number 000-21617 ProPhase Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2577138 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission file number 000-21617 ProPhase Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdic ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2021 Earnings Conference Call May 13, 2021 4:30 AM ET Company Participants Ted Karkus – Chairman and Chief Executive Officer Conference Call Participants Jason Kolbert – Dawson James Robert Danaher – Private Investor Lee Alper – Hammock Investors Pat Patterson – Private Investor Operator Thank you, and good afternoon. I would like to thank you all for taking time to join us for ProPhase Labs First Quarter 2021 Financial Results Conference Call. Your host today is ProPhas ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2020 Results Conference Call March 31, 2021 4:30 PM ET Company Participants Ted Karkus - Chief Executive Officer Monica Brady - Chief Accounting Officer Conference Call Participants Operator Thank you, and good afternoon. I would like to thank you all for taking time to join us for ProPhase Labs Fourth Quarter and Full Year 2020 Financial Results Conference Call. Your host today is ProPhase Labs CEO and Chairman of the Board of Directors, Ted Karkus. A press release deta ...